| URL: | http://bioinfo.vanderbilt.edu/database/Cancer-Immu |
| Full name: | |
| Description: | Cancer-Immu is an open-access resource for exploring associations between onco-immunological genomic data and immunophenotype and thus reveals some important biological conclusions with implications for ICB-based immunotherapy. The Cancer-Immu currently contains 3,652 samples with both ICB response outcome and genomic profiling by either bulk sequencing or single-cell technologies. |
| Year founded: | 2021 |
| Last update: | |
| Version: | |
| Accessibility: |
Accessible
|
| Country/Region: | United States |
| Data type: | |
| Data object: | |
| Database category: | |
| Major species: | |
| Keywords: |
| University/Institution: | Vanderbilt University |
| Address: | |
| City: | |
| Province/State: | |
| Country/Region: | United States |
| Contact name (PI/Team): | Qi Liu |
| Contact email (PI/Helpdesk): | qi.liu@Vanderbilt.Edu |
|
A pan-cancer immunogenomic atlas for immune checkpoint blockade immunotherapy. [PMID: 34903605]
The ability to identify robust genomic signatures that predict response to immune checkpoint blockade is restricted by limited sample sizes and ungeneralizable performance across cohorts. To address these challenges, we established Cancer-Immu (http://bioinfo.vanderbilt.edu/database/Cancer-Immu/) a comprehensive platform that integrates large-scale multidimensional omics data, including genetic, bulk, and single-cell transcriptomic, proteomic, and dynamic genomic profiles, with clinical phenotypes to explore consistent and rare immunogenomic connections. Currently Cancer-Immu has incorporated data for 3,652 samples for 16 cancer types. It provides easy access to immunogenomic data and empowers researchers to translate omics datasets into biological insights and clinical applications. |